Fig. 5From: Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapyPercentage apoptosis in ovarian cancer cells 7-days after azacitidine, carboplatin or combination azacitidine and carboplatin treatment in (A) all cell lines, (B) BRCA-wildtype cell lines, and (C) BRCA-mutant cell lines. Percentage apoptosis is represented as the mean ± SEM of triplicates of three independent experimentsBack to article page